Phase II Study of Rolapitant Plus Olanzapine, Palonosetron, and Dexamethasone in Patients With Germ Cell Tumors Undergoing 5-day Cisplatin-based Chemotherapy.

Phase II study of Rolapitant plus Olanzapine, Palonosetron, and Dexamethasone in patients with germ cell tumors undergoing 5-day Cisplatin-based chemotherapy

开始日期2018-05-31

申办/合作机构

Hoosier Cancer Research Network

[+1]

NCT02991456 / Completed临床2期IIT

Phase II Randomized Study to Evaluate Efficacy, Patient Satisfaction, and Compliance of the Oral Combination of Rolapitant (Varubi®) Plus Ondansetron vs. Ondansetron Monotherapy in Malignant Glioma Patients Receiving Radiotherapy (RT) and Concomitant Temozolomide

The purpose of this phase 2 study is to assess the efficacy and patient satisfaction of oral rolapitant plus ondansetron vs. oral ondansetron monotherapy in malignant glioma (MG) patients receiving standard of care radiation (RT) and temozolomide (TMZ) therapy. This is a randomized phase 2 trial of rolapitant plus ondansetron vs. ondansetron monotherapy for the prevention of chemo-radiation induced nausea and vomiting in primary MG subjects receiving RT and concomitant multi-dose TMZ.

开始日期2017-10-09

申办/合作机构

Duke University

100 项与盐酸罗拉匹坦水合物相关的临床结果

登录后查看更多信息

100 项与盐酸罗拉匹坦水合物相关的转化医学

登录后查看更多信息

100 项与盐酸罗拉匹坦水合物相关的专利（医药）

登录后查看更多信息

项与盐酸罗拉匹坦水合物相关的文献（医药）

2023-10-30·Biotechnology and applied biochemistry

Homology modeling, virtual screening, molecular docking, and ADME approaches to identify a potent agent targeting NK2R protein.

Article

作者: Arash Soltani ; Seyed Isaac Hashemy

Neurokinin/tachykinin receptors are classified as the G-protein coupled receptor superfamily. The neurokinin 2 receptor (NK2R) is widely expressed in different tissues. NK2R is associated with a range of biological events, such as inflammation, smooth muscle contraction, intestinal motor functions, and asthma. Despite these diverse activities, no approved drugs targeting NK2R have been developed yet. Our study focuses on finding potential inhibitors for NK2R using virtual screening, molecular docking, and ADME (absorption, distribution, metabolism, and excretion) approaches. We used a homology modeling approach and AlphaFold DB to obtain the three-dimensional structure of mouse and human NK2R proteins, respectively. The homology model of NK2R was predicted using MODELLER v10.3 and further refined and validated using the 3Drefine tool and RAMPAGE server, respectively. Molecular docking was performed using a library of 910 structurally similar molecules to four NK1R antagonists: aprepitant, casopitant, fosaprepitant, and rolapitant. Molecular docking revealed six small molecules that displayed high Chemscore fitness scores, and binding energies with desirable ligand-NK2R interactions. The evaluation of the in silico ADME profile, solubility, and permeability of the ligand molecules has revealed that the small molecules are potentially nontoxic and have the chance of exhibiting biological activity after oral administration. Further experimental studies (in vitro and in vivo assays) are required to evaluate the effectiveness of these inhibitors as therapeutic targets.

2023-05-24·Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences

Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs.

Article

作者: Subrata Deb ; Robert Hopefl

BACKGROUND:

Chemotherapy-induced nausea and vomiting are commonly experienced side effects in breast cancer (BCa) patients. Antiemetic drugs used in BCa treatment are either inhibitors or inducers of cytochrome P450 (CYP) enzymes, while anticancer drugs are metabolized by CYPs.

OBJECTIVES:

The purpose of the present work was to evaluate in silico drug-drug interaction (DDI) potential between BCa chemotherapeutic drugs and antiemetic agents.

METHODS:

The Drug-Drug Interaction™ module of GastroPlus™ was employed to assess CYP-related interactions between antiemetic and anticancer therapy combinations. The CYP inhibitory or inducing parameters (IC₅₀, K_i, EC₅₀) used in simulations were obtained from the literature.

RESULTS:

Analyses of twenty-three BCa drugs indicated that 22% of the chemotherapeutic drugs do not need an antiemetic agent due to their low emetogenicity, whereas 30% of the anticancer drugs are not metabolized by CYPs. The remaining eleven anticancer drugs metabolized by CYPs generated ninety-nine combinations with nine antiemetics. Simulation of DDIs suggest that about half of the pairs did not demonstrate any potential for DDI, whereas 30%, 10%, and 9% of the pairs showed weak, moderate, and strong interaction potential, respectively. In the present study, netupitant was the only antiemetic that showed strong inhibitory interactions (predicted AUC ratio > 5) with CYP3A4-metabolzied anticancer therapies (e.g., docetaxel, ribociclib, olaparib). Moderate to no interactions were observed with ondansetron, aprepitant, rolapitant, and dexamethasone in combination with anticancer agents.

CONCLUSION:

It is critical to recognize that these interactions can get amplified in cancer patients because of the severity of the disease and chemotherapy toxicities. Clinicians need to be aware of the DDI likelihood of the drug combinations used in BCa treatment.

2022-08-12·Molecules (Basel, Switzerland)

Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2.

Article

作者: Trishna Saha Detroja ; Abraham O Samson

Arginases are often overexpressed in human diseases, and they are an important target for developing anti-aging and antineoplastic drugs. Arginase type 1 (ARG1) is a cytosolic enzyme, and arginase type 2 (ARG2) is a mitochondrial one. In this study, a dataset containing 2115-FDA-approved drug molecules is virtually screened for potential arginase binding using molecular docking against several ARG1 and ARG2 structures. The potential arginase ligands are classified into three categories: (1) Non-selective, (2) ARG1 selective, and (3) ARG2 selective. The evaluated potential arginase ligands are then compared with their clinical use. Remarkably, half of the top 30 potential drugs are used clinically to lower blood pressure and treat cancer, infection, kidney disease, and Parkinson's disease thus partially validating our virtual screen. Most notable are the antihypertensive drugs candesartan, irbesartan, indapamide, and amiloride, the antiemetic rolapitant, the anti-angina ivabradine, and the antidiabetic metformin which have minimal side effects. The partial validation also favors the idea that the other half of the top 30 potential drugs could be used in therapeutic settings. The three categories greatly expand the selectivity of arginase inhibition.

项与盐酸罗拉匹坦水合物相关的新闻（医药）

2023-03-09

·BioSpace

ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development

- Company’s inaugural development candidate, targeting dark genome's first therapeutic target in autoimmune disease, now in IND-enabling studies - BOSTON--(BUSINESS WIRE)-- ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for autoimmune diseases and cancer, today announced the appointment of Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development. Dr. Wilcoxen is a translational leader with more than 25 years of experience advancing new therapies through preclinical and early clinical development, most recently as Senior Vice President, Global Research, at Zenas BioPharma, an autoimmune-focused biotechnology company. “We are pleased to welcome Keith to ROME’s management team at this exciting moment in our company’s growth. We recently nominated ROME’s first development candidate, the LINE-1 reverse transcriptase inhibitor RPT-2950, providing a powerful demonstration of the progress we have made toward illuminating the dark genome’s role in disease,” said Rosana Kapeller, M.D., Ph.D., President, Chief Executive Officer and Co-founder of ROME. “Keith’s expertise in early clinical development and experience leading high-performing scientific teams will be valuable assets as we advance our development candidate to the clinic and progress our pipeline of first-in-class therapies for autoimmune diseases and cancer.” Dr. Wilcoxen’s career spans more than two decades in the biopharmaceutical industry. He joins ROME from Zenas BioPharma where he served as Senior Vice President, Global Research, overseeing all pre-clinical and translational activities for a portfolio of autoimmune therapeutic candidates. Prior to joining Zenas, Dr. Wilcoxen was Vice President of Diligence and Non-Clinical Development, followed by Vice President of Translational Research at Boston Pharmaceuticals where he was a core member of the Research and Development leadership team. In previous roles at TESARO, culminating in the role of Executive Director and Head of Strategic Drug Hunting Partnerships, Preclinical Research, Dr. Wilcoxen supported three Investigational New Drug submissions, including for cancer therapies TSR-011, Jemperli™ (dostarlimab) and cobolimab, and New Drug Application submissions for cancer therapies Varubi™ (rolapitant) and Zejula™ (niraparib). He previously held roles of increasing responsibility with Eisai, Neurocrine Biosciences and Pfizer. Dr. Wilcoxen holds a Ph.D. in chemistry from Scripps Research Institute and a B.A. in chemistry from Northwestern University. “I am excited to join ROME to help drive forward their groundbreaking portfolio of therapies targeting the dark genome’s role in autoimmune diseases and cancer. I believe research into the dark genome is key to the next wave of therapeutic breakthroughs,” said Dr. Wilcoxen. “I look forward to working with the team to bring these important medicines to patients.” About ROME Therapeutics ROME Therapeutics is developing novel therapies for autoimmune diseases and cancer by illuminating the role of the dark genome in human health and disease. Leveraging the company’s unprecedented data sciences platform, ROME has built a deep pipeline of therapies targeting the dark genome. To lead this exploration, ROME has assembled a team of world-class leaders across immunology, oncology, virology and machine learning. ROME is based in Boston, Mass. For more information, please visit .

高管变更临床1期

2023-03-06

·BioSpace

DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors

DiaMedica Continues Building Out Board Of Directors With Key Biopharma Industry Leaders MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Tanya Lewis to its board of directors effective March 1, 2023. Ms. Lewis, a recognized leader in the biopharma industry, brings over 25 years of experience in drug development, having played a key role in the approval of multiple new drugs. Ms. Lewis currently serves as the Chief Development Operations Officer at Replimune Group, Inc. where she has oversight for development of an integrated clinical, regulatory and CMC strategy for the successful registration of the company’s compounds. Ms. Lewis joined the executive management team at Replimune in May 2021 after serving on Replimune’s board of directors since November 2020. Prior to her officer position with Replimune, Tanya was Executive Vice President, Chief Regulatory Strategy and Strategic Operations at Karyopharm Therapeutics Inc., a publicly traded biopharmaceutical company (Nasdaq: KPTI), where she navigated the approval of XPOVIO®. Prior to joining Karyopharm, Ms. Lewis held leadership positions at several companies, including Tesaro and Millennium Pharmaceuticals, where she developed approval strategies and led interactions with U.S. and European regulators for registration trial designs and approvals. Ms. Lewis started her career at Genzyme Corporation in regulatory affairs. Ms. Lewis’s past accomplishments include the successful negotiations for registration trial designs, approval, and/or commercialization of VELCADE®, VARUBI®, INTEGRILIN® and ZEJULA®. “Tanya is a respected and highly accomplished pharmaceutical industry executive with experience in global drug development and regulatory affairs. We’re very excited to have Tanya join our board of directors at this critical time as we work to resolve the clinical hold on our ReMEDy2 AIS trial,” commented Rich Pilnik, DiaMedica’s Board Chairman. Ms. Lewis commented, “DiaMedica is at an exciting moment in its evolution and I look forward to working with the board of directors and management team to help the company on its mission to bring DM199 to benefit the millions of stroke patients without a treatment option today.” Ms. Lewis holds a Bachelor of Science degree in Biology from Northeastern University and a Master of Science degree in Regulatory Affairs and Health Policy from Massachusetts College of Pharmacy and Allied Health Sciences. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit the Company’s website at .

高管变更

2022-06-24

·丁香园

术后恶心还在用甲氧氯普胺？看看正确做法是什么

当碰见患者术后诉恶心呕吐（postoperative nausea and vomiting, PONV），去床旁检查患者排除消化道梗阻情况后，发现病人携带着镇痛泵，嘱患者暂停使用镇痛泵以减少吗啡的副作用。但实际效果不佳，随后带来的是患者诉伤口疼痛。那么应当如何有效防止术后恶心呕吐呢？也许，你曾经用过甲氧氯普胺 10 mg 肌注或静注，但发现该剂量不能有效降低患者术后恶心呕吐，因此可能还会反复用药。事实上，2006 年 BMJ 的一项纳入 3140 名患者的 RCT 表明在成人中 25～50 mg 的甲氧氯普胺与 8 mg 地塞米松联合静脉给药才能有效止吐，但是该剂量下会明显增加低血压、心动过速及锥体外系症状风险。中华医学会麻醉学分会术后恶心呕吐防治专家共识（2014）也指出了胃复安用于 PONV 防治的局限性。术后恶心防治基本原则1.去除基础病因，包括适当术前禁食。例如对于糖尿病伴有胃轻瘫的患者；个别上消化道梗阻患者术前留置胃管抽吸胃内容物；对于术中胃膨胀患者应在手术结東前放入大口径胃管一次性抽吸，抽吸后拔除胃管以减少胃管刺激和返流。2. 确定患者发生 PONV 的风险，根据个体风险分层制定防治策略。无风险患者可不预防性用药，考虑到昂丹司琼价格低，无禁忌症仍建议预防使用；对低、中危患者可选用下述 1 或 2 种药物预防；对高危患者可用 2～3 种药物组合预防。如预防无效应加用不同作用机制的药物治疗。推荐联合用药，其防治 PONV 效果优于单药，且不增加副作用。3. 对未预防用药或预防用药无效的 PONV 患者提供及时的止吐治疗。如果患者术后发生恶心呕吐，在排除药物刺激或机械性因素后，可以开始止吐治疗。术后恶心风险评分女性、非吸烟、有 PONV 史或晕动病史及术后使用阿片类镇痛药是成人 PONV 的四种主要危险因素。根据患者及麻醉因素，Apfel 依此设计了成人 PONV 的风险度简易评分方法：每个因素为 1 分，评分为 0，1，2，3 和 4 分者，发生 PONV 的风险性分别为 10%，20%，40%，60%，80%。临床应用时将其分为以下三类风险人群：1. 低风险，评分为 0 或 1 的患者；2. 中风险，评分为 2 或 3 的患者；3. 高风险，评分为 4 的患者。止吐药的分类恶心呕吐主要是由下列 5 种神经递质受体介导：毒蕈碱样胆碱能受体、组胺 H1 受体、多巴胺 D2 受体、5-羟色胺（5-HT3）受体以及神经激肽 1（NK-1）受体。针对所有这些受体的药物都可能预防和治疗 PONV。1. 抗胆碱药：这类药物作用机制是抑制毒蕈碱样胆碱能受体，并抑制乙酰胆碱释放。该类药物可主要用于治疗运动病、眩晕、病毒性内耳炎、梅尼埃病和肿瘤所致的恶心呕吐。代表药物：东莨菪碱贴剂，对预防 PONV 的效果与昂丹司琼和氟哌利多相当。2. 抗组胺药：组胺受体可分为 H1、H2 和 H3 三种类型。与恶心呕吐密切相关的是 H1 受体，其拮抗剂主要用于晕动病。代表药物：苯海拉明，止吐效果与地塞米松、氟哌利多以及 5-HT3 拮抗剂效果相似。3. 多巴胺 D2 受体拮抗剂：吩噻嗪类：治疗阿片类药物所致恶心呕吐非常有效的药物。在 PONV 的应用受限于其大剂量时的镇静作用及锥体外系作用，通常不用于儿童。代表药物：奋乃静、异丙嗪（同时拮抗 H1 受体）及丙氯拉嗪，后者为此类药物中最常用的止吐药。丁酰苯类：是抗精神病药物，代表药物为氟哌利多和氟哌啶醇。在预防 PONV 方面，低剂量使用该类药物与昂丹司琼止吐效果一样，且同样应避免用于有 QT 间期延长的患者。昂丹司琼联合氟哌利多或联合氟哌啶醇比单用其中任何一种药物都更有效。此外，氟哌啶醇被推荐为氟哌利多的替代品。苯甲酰胺类：代表药物为甲氧氯普胺和多潘立酮。甲氧氯普胺以标准剂量用药时具有轻微止吐作用。该药还可加速胃轻瘫患者的胃排空，增加下食管括约肌张力。目前主要用作预防顺铂所致迟发性呕吐的辅助药物，不建议用于预防 PONV。多潘立酮是 D2 受体阻滞剂，在上消化道中具有选择性外周阻滞作用。该药不通过血-脑屏障，因此没有甲氧氯普胺的神经系统副作用，但可增加严重室性心律或心源性猝死的风险，不应与延长 QT 间期的其他药物同时使用。4. 5-HT3 受体拮抗剂：常用于预防和治疗 PONV。此类药物无镇静作用，是术后应用的一个优势。建议用于 PONV 的预防，特别是高危患者的预防，但是不推荐使用多次治疗剂量，如果无效应试用另一类药物。a. 第一代 5-HT3 受体拮抗剂：昂丹司琼、格拉司琼、多拉司琼及托烷司琼，这些药物在等效剂量下预防 PONV 效果相当。应避免用于有 QT 间期延长的患者。b. 第二代 5-HT3 受体拮抗剂：帕洛诺司琼。相比第一代 5-HT3 受体拮抗剂，其具有更强的受体亲和力以及更长的半衰期（40 h），更适用于后期及出院后恶心呕吐的预防，且并不影响 QT 间期。5. 神经激肽 1（NK-1）受体拮抗剂：这是一类较新型的长效止吐药，单用阿瑞匹坦与单用昂丹司琼相比，以及阿瑞匹坦联用地塞米松与昂丹司琼联用地塞米松相比，预防 PONV 效果相当。最新的罗拉匹坦对于预防术后 72 小时和 120 小时的呕吐效果优于昂丹司琼。6. 糖皮质激素：地塞米松、5-HT3 受体抑制药和氟哌啶醇是预防 PONV 最有效且副作用小的药物。一剂地塞米松不增加切口感染发生，还可减少术后疼痛和术后阿片类药物的使用需求。需要注意的是：糖耐量受损患者中应用地塞米松后注意 6-12 小时内血糖可能升高。预防 PONV 方案常用预防 PONV 药物的使用剂量和时间注意：氟哌利多已经不再是一线药物，只有其他药物无效才可使用；静脉抗呕吐药则在手术结束前静注，但静脉制剂地塞米松应在麻醉诱导后给予；东莨菪碱贴剂应在手术前晚上或手术开始前 2～4 h 给予。补救性治疗方案1. 如果病人没有预防性用药，第一次出现 PONV 时，应开始小剂量 5-HT3 受体拮抗药治疗。5-HT3 受体拮抗药的治疗剂量通常约为预防剂量的 1/4，可按照如下推荐剂量给药：昂丹司琼 1 mg、多拉司琼 12.5 mg、格拉司琼 0.1 mg 和托烷司琼 0.5 mg。也可给予地塞米松 2～4 mg，氟哌啶醇 0.5～2 mg，或异丙嗪 6.25～12.5 mg。2. 如果已预防性用药，则治疗时应换用其它类型药物。补救性方案应包括一种与预防用药不同种类的止吐药，除非之前的药效已经消失。3. 如果在三联疗法（如 5-HT3 受体抑制药、地塞米松和氟哌利多或氟哌啶醇）预防后病人仍发生 PONV。如果 PONV 在术后 6 h 以后发生，可考虑重复给予 5-HT3 受体拮抗药和氟哌利多或氟哌啶醇，剂量同前。不推荐重复应用地塞米松。如果 PONV 在术后 6 h 内发生，则不应重复使用三联疗法药物，应换用其他止吐药。例如：a. 苯海拉明 1 mg/kg 静脉注射（儿童用量减半，且不超过 25 mg），每 6 小时 1 次；b. 异丙嗪 12.5～25 mg 肌内注射，每 4 小时 1 次；c. 丙氯拉嗪 5～10 mg 肌内注射，或 2.5～10 mg 静脉给药，每 3～4 小时 1 次；总结术后恶心呕吐在全麻手术后较常见，手术时间越长，PONV 发生率越高，尤其是持续 3 h 以上的手术。住院患者中 20%～30% 会经历 PONV，通常发生在手术后 24～48 h 内，少数患者持续时间可达 3～5 天。PONV 可以导致患者不同程度的不适，轻者影响正常进食服药；重者可致伤口裂开、切口疝形成、食管撕裂、误吸入性肺炎、脱水、颅内高压及气胸。因此，良好的 PONV 预防和处理能增加患者术后满意度、节约医疗费用及降低并发症的发生。而且，使用上述策略积极处理 PONV，大多患者在 24 小时内好转。各类止吐药物的使用根据医师及患者的偏好，其临床防治 PONV 的效果判定金标准是达到 24 小时有效和完全无恶心呕吐。如果先前的药物不起效或效果减退和使用其他药物。编辑：刘海洋参考文献：[1] Wallenborn J, Gelbrich G, Bulst D, et al. Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial.[J]. BMJ (Clinical research ed.), 2006, 333(7563): 324.[2] 中华医学会麻醉学分会. 术后恶心呕吐防治专家共识（2014）[EB/OL][2020-05-31].[3] Apfel C C, Läärä E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers.[J]. Anesthesiology, 1999, 91(3): 693–700.[4] White P F, Tang J, Song D, et al. Transdermal scopolamine: an alternative to ondansetron and droperidol for the prevention of postoperative and postdischarge emetic symptoms.[J]. Anesthesia and analgesia, 2007, 104(1): 92–96.[5] Kranke P, Morin A M, Roewer N, et al. Dimenhydrinate for prophylaxis of postoperative nausea and vomiting: a meta-analysis of randomized controlled trials.[J]. Acta anaesthesiologica Scandinavica, 2002, 46(3): 238–244.[6] Tj G, J G, N S, et al. Rolapitant for the Prevention of Postoperative Nausea and Vomiting: A Prospective, Double-Blinded, Placebo-Controlled Randomized Trial[EB/OL][2020-05-31]. https://pubmed.ncbi.nlm.nih.gov/21385988/?from_single_result = 21385988&expanded_search_query = 21385988.[7] Apfel C C, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting.[J]. The New England journal of medicine, 2004, 350(24): 2441–2451.[8] Toner A J, Ganeshanathan V, Chan M T, et al. Safety of Perioperative Glucocorticoids in Elective Noncardiac Surgery: A Systematic Review and Meta-analysis.[J]. Anesthesiology, 2017, 126(2): 234–248.[9] Tien M, Gan T J, Dhakal I, et al. The effect of anti-emetic doses of dexamethasone on postoperative blood glucose levels in non-diabetic and diabetic patients: a prospective randomised controlled study.[J]. Anaesthesia, 2016, 71(9): 1037–1043.‍‍

100 项与盐酸罗拉匹坦水合物相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08988	盐酸罗拉匹坦水合物	A04AD	DB09291

研发状态

适应症	最高研发状态	国家/地区	公司
恶心	批准上市	美国更多	TerSera Therapeutics LLC初创企业更多
呕吐	批准上市	美国更多	TerSera Therapeutics LLC初创企业更多
延迟性恶心和呕吐	撤市	美国更多	TerSera Therapeutics LLC初创企业更多
化疗引起的恶心和呕吐	撤市	挪威更多	Tesaro Bio Netherlands BV 更多
咳嗽	终止	英国更多	Schering-Plough Corp. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01500226 (Pubmed) 人工标引	临床3期	恶心 \| 肿瘤 \| 呕吐	1,369	granisetron+dexamethasone+rolapitant	(鹹鏇餘簾齋壓鹹範衊糧) = 顧簾網網繭廠艱觸範壓選網醖夢構鑰製積繭網 (繭艱衊壓積獵蓋鑰餘築 ) 更多	积极	2015-09-01
				granisetron+dexamethasone+Placebo	(鹹鏇餘簾齋壓鹹範衊糧) = 憲壓膚繭膚遞構憲構窪選網醖夢構鑰製積繭網 (繭艱衊壓積獵蓋鑰餘築 ) 更多
NCT01500226 (ASCO2014)	临床3期	-	1,369	Rolapitant + granisetron + dexamethasone	(觸蓋糧觸鹹製鏇積窪鏇) = 壓鬱餘範艱淵窪網範艱製築鏇鑰範壓淵蓋壓鬱 (網積艱憲製築範鹹廠膚 ) 更多	积极	2014-05-20
				Placebo + granisetron + dexamethasone	(觸蓋糧觸鹹製鏇積窪鏇) = 遞壓淵鏇憲壓艱願鏇壓製築鏇鑰範壓淵蓋壓鬱 (網積艱憲製築範鹹廠膚 ) 更多
ASCO2012	临床2期	-	454	Rolapitant 200mg	糧襯廠繭蓋繭壓憲築願(築膚壓夢淵醖夢遞簾遞) = achieved statistically significant better QoL scores (FLIE questionnaire) compared to the placebo group 遞遞鹹鏇顧繭選範衊鏇 (鏇糧衊願艱夢齋鹹構簾 )	积极	2012-05-20
NCT02991456 (CTgov)	临床2期	放疗引起的恶心和呕吐 \| 胶质瘤	48	Ondansetron+Rolapitant (Sequence A)	顧壓積襯簾遞淵糧衊淵(繭鬱淵獵願憲醖壓選廠) = 齋願壓選網願製膚鹽選網夢簾艱鬱廠觸鑰齋糧 (憲構觸鬱築願範餘鏇簾, 夢鹽鬱窪鹹繭選艱齋鬱 ~ 醖觸願遞襯鑰簾蓋繭鹽) 更多	-	2023-07-11
				Ondansetron+Rolapitant (Sequence B)	顧壓積襯簾遞淵糧衊淵(繭鬱淵獵願憲醖壓選廠) = 網獵積夢願壓選鹽膚選網夢簾艱鬱廠觸鑰齋糧 (憲構觸鬱築願範餘鏇簾, 鹹襯簾選窪餘鏇膚廠壓 ~ 齋襯網衊網憲獵醖衊憲) 更多
NCT01500226 (ASCO2014)	临床3期	化疗引起的恶心和呕吐	1,369	Rolapitant 200 mg + granisetron + dexamethasone	(鹹醖襯鬱壓簾齋醖選壓) = 蓋鑰構蓋蓋積膚鹹構鏇蓋蓋鹹簾窪願積蓋蓋願 (繭鏇鏇獵窪積鬱觸製網 ) 更多	-	2014-05-20
				Placebo + granisetron + dexamethasone	(鹹醖襯鬱壓簾齋醖選壓) = 鏇構衊窪築衊觸鑰範憲蓋蓋鹹簾窪願積蓋蓋願 (繭鏇鏇獵窪積鬱觸製網 ) 更多
NCT01500213 (ASCO2014)	临床3期	脑积水，心内膜纤维弹性增生和白内障	555	Rolapitant + granisetron + dexamethasone	(鑰製餘壓繭膚鬱簾鏇願) = 顧簾膚糧製襯選鹹餘積廠範襯齋鬱範廠夢鹽構 (窪廠壓膚繭窪餘襯鏇鏇 ) 更多	积极	2014-05-20
				Placebo + granisetron + dexamethasone	(鑰製餘壓繭膚鬱簾鏇願) = 積網鹹選鑰廠觸襯憲膚廠範襯齋鬱範廠夢鹽構 (窪廠壓膚繭窪餘襯鏇鏇 ) 更多
NCT01500213 (CTgov)	临床3期	化疗引起的恶心和呕吐	555	Placebo+Granisetron+Dexamethasone	夢鏇選衊廠築壓遞衊糧(蓋選蓋廠廠鬱繭鏇範蓋) = 齋淵廠顧齋觸積製觸夢糧憲鑰艱鏇觸壓淵顧願 (夢鏇遞積範蓋遞顧網廠, 獵淵艱鏇積簾鑰窪顧顧 ~ 廠鹽夢襯鑰獵遞蓋積獵) 更多	-	2015-11-04
NCT02732015 (CTgov)	临床2期	局部晚期软组织肉瘤 \| 呕吐 \| 恶心	37	Ondansetron (5HT3 receptor antagonist)+Dexamethasone+Rolapitant (Cohort 1)	(艱淵願願觸獵廠夢憲鏇) = 鏇願醖壓選願製壓醖積鑰範選簾選夢窪網鹹顧 (願憲膚衊遞醖鑰構範糧, 襯艱製觸艱觸獵願鏇願 ~ 廠鏇選糧壓觸蓋餘繭網) 更多	-	2021-08-09
				Ondansetron (5HT3 receptor antagonist)+Dexamethasone+Rolapitant (Cohort 2)	(艱淵願願觸獵廠夢憲鏇) = 觸鹹夢製膚願範襯淵襯鑰範選簾選夢窪網鹹顧 (願憲膚衊遞醖鑰構範糧, 鑰積築憲築齋膚糧範壓 ~ 餘蓋齋觸憲壓顧膚築餘) 更多
NCT01500226 (CTgov)	临床3期	化疗引起的恶心和呕吐	1,369	placebo+Granisetron+Dexamethasone	鹽糧夢憲築淵醖築憲遞(壓觸鬱製築餘膚齋蓋壓) = 醖鹹膚選壓蓋獵廠壓夢壓夢齋築鏇積製壓醖襯 (構醖鬱淵鏇鏇鑰襯繭遞, 夢範廠顧鑰壓鑰觸鑰顧 ~ 襯淵夢選壓觸餘範遞積) 更多	-	2015-11-04
Pubmed	临床3期	化疗引起的恶心和呕吐	-	Rolapitant	(鏇獵憲齋壓餘鬱艱鑰廠) = 繭構窪顧鹽齋簾築繭製構範積顧獵構糧憲顧糧 (願艱壓繭蓋壓鏇簾艱選 )	积极	2015-09-01
				Active control	(鏇獵憲齋壓餘鬱艱鑰廠) = 製製膚鹽窪蓋蓋蓋鏇網構範積顧獵構糧憲顧糧 (願艱壓繭蓋壓鏇簾艱選 )